BACKGROUND: Pharmacogenetic studies of drug response in asthma assume that patients respond consistently to a treatment but that treatment response varies across patients; however, no formal studies have demonstrated this. OBJECTIVE: To determine the repeatability of commonly used outcomes for treatment response to asthma medications: bronchodilator response, FEV(1), and PC(20). METHODS: The Childhood Asthma Management Program was a multicenter clinical trial of children randomized to receiving budesonide, nedocromil, or placebo. We determined the intraclass correlation coefficient (ICC) for each outcome over repeated visits over a period of 4 years in the Childhood Asthma Management Program by using mixed-effects regression models. We adjusted for the covariates age, race/ethnicity, height, family income, parental education, and symptom score. We incorporated each outcome for each child as repeated outcome measurements and stratified by treatment group. RESULTS: The ICC for bronchodilator response was 0.31 in the budesonide group, 0.35 in the nedocromil group, and 0.40 in the placebo group, after adjusting for covariates. The ICC for FEV(1) was 0.71 in the budesonide group, 0.60 in the nedocromil group, and 0.69 in the placebo group, after adjusting for covariates. The ICC for PC(20) was 0.67 in the budesonide and placebo groups and 0.73 in the nedocromil group, after adjusting for covariates. CONCLUSION: The within-treatment group repeatability of FEV(1) and PC(20) is high; thus, these phenotypes are heritable. FEV(1) and PC(20) may be better phenotypes than bronchodilator response for studies of treatment response in asthma.
RCT Entities:
BACKGROUND: Pharmacogenetic studies of drug response in asthma assume that patients respond consistently to a treatment but that treatment response varies across patients; however, no formal studies have demonstrated this. OBJECTIVE: To determine the repeatability of commonly used outcomes for treatment response to asthma medications: bronchodilator response, FEV(1), and PC(20). METHODS: The Childhood Asthma Management Program was a multicenter clinical trial of children randomized to receiving budesonide, nedocromil, or placebo. We determined the intraclass correlation coefficient (ICC) for each outcome over repeated visits over a period of 4 years in the Childhood Asthma Management Program by using mixed-effects regression models. We adjusted for the covariates age, race/ethnicity, height, family income, parental education, and symptom score. We incorporated each outcome for each child as repeated outcome measurements and stratified by treatment group. RESULTS: The ICC for bronchodilator response was 0.31 in the budesonide group, 0.35 in the nedocromil group, and 0.40 in the placebo group, after adjusting for covariates. The ICC for FEV(1) was 0.71 in the budesonide group, 0.60 in the nedocromil group, and 0.69 in the placebo group, after adjusting for covariates. The ICC for PC(20) was 0.67 in the budesonide and placebo groups and 0.73 in the nedocromil group, after adjusting for covariates. CONCLUSION: The within-treatment group repeatability of FEV(1) and PC(20) is high; thus, these phenotypes are heritable. FEV(1) and PC(20) may be better phenotypes than bronchodilator response for studies of treatment response in asthma.
Authors: Stanley J Szefler; Richard J Martin; Tonya Sharp King; Homer A Boushey; Reuben M Cherniack; Vernon M Chinchilli; Timothy J Craig; Myrna Dolovich; Jeffrey M Drazen; Joanne K Fagan; John V Fahy; James E Fish; Jean G Ford; Elliot Israel; James Kiley; Monica Kraft; Stephen C Lazarus; Robert F Lemanske; Elizabeth Mauger; Stephen P Peters; Christine A Sorkness Journal: J Allergy Clin Immunol Date: 2002-03 Impact factor: 10.793
Authors: Stanley Szefler; Scott Weiss; James Tonascia; N Franklin Adkinson; Bruce Bender; Reuben Cherniack; Michele Donithan; H William Kelly; Joseph Reisman; Gail G Shapiro; Alice L Sternberg; Robert Strunk; Virginia Taggart; Mark Van Natta; Robert Wise; Margaret Wu; Robert Zeiger Journal: N Engl J Med Date: 2000-10-12 Impact factor: 91.245
Authors: Linda Y Tang; Hui Cai; Udayakumar Navaneethan; James H Boone; Sarah J Rhodes; Lauren Moore; Hyunjin Rho; Carol de La Motte; Elaine Queener; Bo Shen Journal: Int J Colorectal Dis Date: 2012-03-20 Impact factor: 2.571
Authors: E B Mougey; C Chen; K G Tantisira; K V Blake; S P Peters; R A Wise; S T Weiss; J J Lima Journal: Pharmacogenomics J Date: 2012-02-28 Impact factor: 3.550
Authors: Aparna Chhibber; Deanna L Kroetz; Kelan G Tantisira; Michael McGeachie; Cheng Cheng; Robert Plenge; Eli Stahl; Wolfgang Sadee; Marylyn D Ritchie; Sarah A Pendergrass Journal: Pharmacogenomics Date: 2014-12 Impact factor: 2.533
Authors: Michael J McGeachie; Eli A Stahl; Blanca E Himes; Sarah A Pendergrass; John J Lima; Charles G Irvin; Stephen P Peters; Marylyn D Ritchie; Robert M Plenge; Kelan G Tantisira Journal: Pharmacogenet Genomics Date: 2013-06 Impact factor: 2.089
Authors: Blanca E Himes; Weiliang Qiu; Barbara Klanderman; John Ziniti; Jody Senter-Sylvia; Stanley J Szefler; Robert F Lemanske; Robert S Zeiger; Robert C Strunk; Fernando D Martinez; Homer Boushey; Vernon M Chinchilli; Elliot Israel; David Mauger; Gerard H Koppelman; Maartje A E Nieuwenhuis; Dirkje S Postma; Judith M Vonk; Nicholas Rafaels; Nadia N Hansel; Kathleen Barnes; Benjamin Raby; Kelan G Tantisira; Scott T Weiss Journal: BMC Med Genet Date: 2013-08-28 Impact factor: 2.103
Authors: Amber Dahlin; Joanne E Sordillo; Michael McGeachie; Rachel S Kelly; Kelan G Tantisira; Sharon M Lutz; Jessica Lasky-Su; Ann Chen Wu Journal: PLoS One Date: 2020-03-02 Impact factor: 3.240